The 5-HT1A receptor knockout mouse and anxiety

被引:69
作者
Olivier, B
Pattij, T
Wood, SJ
Oosting, R
Sarnyai, Z
Toth, M
机构
[1] Univ Utrecht, Fac Pharm, Dept Psychopharmacol, NL-3584 CA Utrecht, Netherlands
[2] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[3] Cornell Univ, Joan & Sanford I Weil Coll, Dept Pharmacol, New York, NY USA
[4] Univ Utrecht, Fac Pharm, Dept Pharmaceut Proteom, Utrecht, Netherlands
[5] PsychoGen Inc, Hawthorne, NY USA
[6] Rockefeller Univ, Dept Neuroendocrinol, New York, NY 10021 USA
来源
BEHAVIOURAL PHARMACOLOGY | 2001年 / 12卷 / 6-7期
关键词
anxiety; 5-HT1A receptor; knockout; genetic background; strain; mouse; GABA(A)-benzodiazepine receptor complex;
D O I
10.1097/00008877-200111000-00004
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The 5-HT1A receptor has been implicated in the modulation of anxiety processes, mainly via pharmacological experiments. The recent production, in three independent research groups, of 5-HT1A receptor knockout (R KO) mice in three different genetic backgrounds (C57BL/6J, 129/Sv, Swiss-Webster) led to the intriguing finding that all mice, independent from the genetic background strain from which the null mutants were made, showed an 'anxious' phenotype compared to corresponding wild-type mice. The present paper reviews the behavioral findings in these three KO lines and focuses on new findings in the 129/Sv-KO mice. These mice were more anxious or stress-prone only under specific conditions (high stress) and not as broadly as suggested from the initial studies. The 5-HT1A R KO made in the Swiss-Webster background displays disturbances in the GABA(A)-benzodiazepine (BZ) receptor system in the brain, including downregulation of GABAA alpha (1) and alpha (2) subunits in the amygdala. In contrast, the GABA(A)-BZ receptor system seems to function normally in the 5-HT1A R KO in the 129/Sv background suggesting that changes in the GABA(A)-BZ receptor system may not be a prerequisite for anxiety but rather could have a modifying effect on this phenotype. It can be concluded that the constitutive absence of the 5-HT1A receptor gene and receptor leads to a more 'anxious' mouse, dependent on the stress level but independent from the strain. Depending on the genetic background, this null mutation may be associated with changes in GABA(A)-ergic neurotransmission. It is as yet unclear which mechanisms are involved in this intriguing differentiation. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:439 / 450
页数:12
相关论文
共 61 条
[1]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[2]   ANXIOGENIC EFFECTS OF METHYL-BETA-CARBOLINE-3-CARBOXYLATE IN A LIGHT DARK CHOICE SITUATION [J].
BELZUNG, C ;
MISSLIN, R ;
VOGEL, E ;
DODD, RH ;
CHAPOUTHIER, G .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 28 (01) :29-33
[3]   Stress-induced hyperthermia in mice: effects of flesinoxan on heart rate and body temperature [J].
Bouwknecht, JA ;
Hijzen, TH ;
van der Gugten, J ;
Maes, RAA ;
Olivier, B .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 400 (01) :59-66
[4]  
BUREAU M, 1990, MOL PHARMACOL, V37, P497
[5]   Anxiolytic-like profile of p-MPPI, a novel 5HT(1A) receptor antagonist, in the murine elevated plus-maze [J].
Cao, BJ ;
Rodgers, RJ .
PSYCHOPHARMACOLOGY, 1997, 129 (04) :365-371
[6]   Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice .2. WAY 100635, SDZ 216-525 and NAN-190 [J].
Cao, BJ ;
Rodgers, RJ .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 58 (02) :593-603
[7]   Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice [J].
Cao, BJ ;
Rodgers, RJ .
PSYCHOPHARMACOLOGY, 1998, 139 (03) :185-194
[8]   GABAergic influences on plus-maze behaviour in mice [J].
Dalvi, A ;
Rodgers, RJ .
PSYCHOPHARMACOLOGY, 1996, 128 (04) :380-397
[9]  
DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1
[10]   SHOCK-INDUCED ULTRASONIC VOCALIZATION IN YOUNG-ADULT RATS - A MODEL FOR TESTING PUTATIVE ANTI-ANXIETY DRUGS [J].
DEVRY, J ;
BENZ, U ;
SCHREIBER, R ;
TRABER, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 249 (03) :331-339